VRTX Is Down 10% After 517 Days. What History Says Now

VRTX Recovered to the Green Zone. What History Suggests

As of June 22, 2026, Vertex Pharmaceuticals Incorporated (VRTX) has officially transitioned from the yellow zone back into the green zone, with its current price of $466.79 sitting -9.7% below its all-time high of $516.74. This recovery milestone prompts an important question: where do the company's valuation percentiles now sit within its own historical record? Our data shows that despite the price recovery, the Price-to-Sales (P/S) percentile and the EV-to-EBITDA (EV/EBITDA) percentile remain positioned in the lower tiers of the stock's historical range. Specifically, the multiples have not reverted to their long-term medians, indicating that the stock's valuation remains low relative to its own past.

Defining the Drawdown Severity Score™ and Zone Transitions

The transition from the yellow zone to the green zone indicates a measurable reduction in downside risk according to our tracking models. The proprietary Drawdown Severity Score™ for VRTX now sits at 1.6, which classifies the stock as "Slightly Elevated" within the green zone. This score represents an improvement from its previous yellow zone status, which signifies moderate risk and deeper price contractions.

The stock has spent 517 days in its current drawdown period, demonstrating a prolonged consolidation phase since reaching its historical peak. A drawdown of -9.7% is a common occurrence for this asset, but the duration of this specific event sets it apart from typical pullbacks. While the severity score has decreased to 1.6, the length of the recovery window suggests that the market has taken a highly measured path to revalue the company. Our data tracks these shifts to help investors understand the historical context of each price contraction.

We categorize drawdown severity to filter out short-term market noise from structural trend changes. The green zone indicates that the asset is operating within normal historical volatility parameters, even if it remains below its peak. By contrast, the yellow zone serves as an early warning indicator that a stock is experiencing selling pressure beyond its typical baseline. The current score of 1.6 shows that VRTX has stabilized and is no longer exhibiting the elevated risk characteristics that triggered the yellow zone alert.

Valuation Versus Its Own Record

To understand where VRTX stands today, we look at how its valuation multiples rank against its own historical data. As of 2026-06-20, the Price-to-Sales (P/S) ratio for VRTX is 9.4, which sits in the 21st percentile of its own daily P/S record since 2006-06-19. This is below its typical historical range, where the historical median P/S ratio is 14.7. This indicates that the current sales multiple is low compared to how the market has historically priced the company's revenue.

The EV-to-EBITDA (EV/EBITDA) ratio shows a similar, though slightly less pronounced, positioning. As of 2026-06-20, the EV/EBITDA ratio is 20.8, placing it in the 32nd percentile of its own daily EV/EBITDA record since 2012-02-22. This ratio remains within its typical historical range, though it sits below the historical median of 27.7. When a stock's valuation percentiles are low relative to its own history, it shows that the market is paying less per unit of sales and earnings than it typically has in the past. We provide this data strictly as historical context, and it does not constitute a recommendation to buy or sell VRTX.

The divergence between the price recovery and the valuation percentiles is a key structural feature of the current market state. Even though the stock price has climbed back toward its all-time high, the underlying sales and earnings have grown fast enough to keep the multiples low relative to history. This suggests that the price recovery is backed by fundamental financial growth rather than speculative multiple expansion. Investors tracking VRTX can use these percentiles to evaluate whether the stock is trading at a premium or a discount relative to its own long-term historical standards.

Historical Analysis of Vertex Pharmaceuticals Drawdowns

Analyzing VRTX's historical drawdown patterns provides deep context for the current 517-day recovery cycle. Throughout its trading history, VRTX has experienced 131 total historical drawdown events. The average maximum drawdown across all historical events is -9.6%, which is nearly identical to the current drawdown of -9.7%. However, the current duration of 517 days far exceeds the average drawdown duration of 91 days.

When we look at comparable drops of 5% or more, VRTX has experienced such declines 60 times in its history. The average duration of these comparable drops is 191 days. The current 517-day period is more than double the historical average for similar declines, showing that this recovery has been exceptionally slow.

The data shows that while the depth of the current drop (-9.7%) aligns closely with the historical average max drawdown of -9.6%, the time required to work through this pullback has been highly unusual. In most historical instances, VRTX has recovered its peak pricing much faster. This prolonged timeline suggests a structural shift in investor sentiment or a longer-term consolidation phase.

By comparing the current 517-day duration against the 191-day average for comparable drops of 5% or more, we can see the extent of this delay. This is not a standard, rapid V-shaped recovery. Instead, VRTX has spent over a year grinding through a wide consolidation range before finally stabilizing in the green zone. This extended duration may reflect broader sector-wide headwinds or a transition period in the company's product pipeline.

Market Drivers Behind the VRTX Rebound

Recent market activity explains some of the upward momentum that pushed VRTX back into the green zone. On June 22, 2026, VRTX closed up by 3.45%, outperforming the broader market, according to a report by TradingKey. This daily gain occurred during a session where the wider market experienced downward pressure, as highlighted by Yahoo Finance in their coverage of why the market dipped while Vertex Pharmaceuticals gained.

A key fundamental driver behind this relative strength is progress within the company's clinical pipeline. According to a report by Simply Wall St, strong pediatric CASGEVY data has positively impacted the investment narrative surrounding the company's gene therapy programs. CASGEVY, a CRISPR-based gene-editing therapy developed in partnership with CRISPR Therapeutics, continues to be a focal point for institutional investors assessing the company's long-term growth pipeline. This clinical progress has provided a fundamental anchor for the stock as it attempts to reclaim its previous high of $516.74.

The contrast between VRTX's performance and the broader healthcare sector has also drawn attention. Barchart.com recently raised the question of whether Vertex Pharmaceuticals was underperforming the healthcare sector, highlighting the stock's relative divergence from its peers. The recent price action and the transition to the green zone suggest that VRTX may be starting to close that performance gap. Institutional interest remains high, as reflected in discussions on Yahoo Finance regarding whether VRTX remains a strong selection for healthcare-focused portfolios.

Key Risk Metrics and Severity Thresholds to Monitor

While VRTX has successfully transitioned to the green zone, several risk metrics merit ongoing observation. Investors should monitor whether the Drawdown Severity Score™ begins to climb back toward the yellow zone threshold. A drop below the current price of $466.79 would increase the drawdown depth past -9.7%, potentially triggering a shift in the Drawdown Severity Score™.

Additionally, tracking the valuation percentiles in future data updates will reveal whether the price recovery is driven by multiple expansion or fundamental earnings growth. If the P/S ratio rises from its 21st percentile toward the historical median of 14.7, it would indicate expanding investor willingness to pay a premium for Vertex's sales. Conversely, if the EV/EBITDA ratio slips below the 32nd percentile, it may indicate that earnings growth is outpacing price appreciation. We will continue to track these metrics to provide objective, data-driven updates on VRTX's risk profile.

Another critical factor to watch is how the stock behaves if it approaches its all-time high of $516.74. Historically, stocks often face resistance as they near previous peaks, especially after a prolonged drawdown period like the current 517-day cycle. If VRTX fails to break through this level, it could establish a double-top pattern, which would increase the likelihood of a return to the yellow zone. Monitoring our proprietary severity score will provide early indications of whether the stock is maintaining its upward momentum or beginning to roll over.